Nissen and his colleagues revisited their original analysis, adding new data from studies completed in the last three years.

FORBES: Why Avandia Will Change The Drug Industry

Thomsen says new data from recently completed two-year human studies of liraglutide show no hints of thyroid problems in roughly 1, 500 patients.

FORBES: Drug Safety

In that study, researchers looked at the data from two already completed studies, the Vioxx Gastrointestinal Outcomes Research study (VIGOR) and Celecoxib Long-Term Arthritis Safety Study (CLASS), and concluded that both drugs might slightly increase the risk of cardiac events such as heart attack and stroke.

FORBES: Magazine Article